Targeting Semaphorin 7a signaling in preclinical models of estrogen receptor-positive breast cancer
Rachel N. Steinmetz, Veronica M. Wessells, Heather Fairchild, Traci Renae Lyons
This study investigates SEMA7A's role in ER+ breast cancer resistance to endocrine therapy and shows that targeting SEMA7A with antibodies or PI3K inhibitors reduces tumor growth in preclinical models.
bioRxiv · May 21, 2025 · PreprintCancer Biology